Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease

Bone Marrow Transplant. 2024 Feb;59(2):282-284. doi: 10.1038/s41409-023-02165-3. Epub 2023 Dec 9.

Authors

Iskra Pusic¹, Catherine Lee², Muthu Veeraputhiran³, Chelsea Minor⁴, John F DiPersio⁴

Affiliations

¹ Washington University School of Medicine, Division of Oncology, St. Louis, MO, USA. iskrapusic@wustl.edu.
² Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA, USA.
³ University of Arkansas for Medical Sciences, Department of Hematology and Medical Oncology, Little Rock, AR, USA.
⁴ Washington University School of Medicine, Division of Oncology, St. Louis, MO, USA.

PMID: 38071272
DOI: 10.1038/s41409-023-02165-3

No abstract available

Publication types

Letter

MeSH terms

Acetamides*
Bronchiolitis Obliterans Syndrome*
Chronic Disease
Graft vs Host Disease* / drug therapy
Hematopoietic Stem Cell Transplantation*
Humans
Nitriles
Pyrazoles*
Pyrimidines

Substances

ruxolitinib
belumosudil
Nitriles
Pyrimidines
Acetamides
Pyrazoles